Evidence map›Paper›PMID 41266253›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Claudin 18.2 as a Biomarker for Imaging and Radiopharmaceutical Therapy in Gastric and Pancreatic Tumors.

Shvan J Raheem, Santosh Bashyal, Arvin Haj-Mirzaian, Yousef Khazaei Monfared, Umar Mahmood, Pedram Heidari, Matthew R Strickland, David T Ting, Samuel J Klempner, Benjamin M Larimer and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Claudin 18.2 Targeting: A Pan-Cancer Perspective.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  2. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shvan J RaheemDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Santosh BashyalDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Arvin Haj-MirzaianDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Yousef Khazaei MonfaredDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Umar MahmoodDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Pedram HeidariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Matthew R StricklandDivision of Hematology-Oncology, Mass General Brigham Cancer Institute, and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and.
David T TingDivision of Hematology-Oncology, Mass General Brigham Cancer Institute, and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and.
Samuel J KlempnerDivision of Hematology-Oncology, Mass General Brigham Cancer Institute, and Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and.
Benjamin M LarimerDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; esfahani.shadi@mgh.harvard.edu.

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
Enhancing the therapeutic effect of receptor radionuclide therapy in neuroendocrine tumors by somatostatin receptor upregulationK08CA249047 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDARI, PEDRAM · 2020 to 2024
$1.3M
Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA249047NCI NIH HHS K08 CA259626NCI NIH HHS P50 CA127003
6 · The paper itself

Abstract

Claudin 18.2 (CLDN18.2) is a tight-junction protein overexpressed and differently exposed in solid tumors such as gastric cancer (GCa), gastroesophageal junction adenocarcinoma, and pancreatic ductal adenocarcinoma (PDAC). We sought to explore the potential of CLDN18.2 as a biomarker for molecular imaging and targeted radiopharmaceutical therapy in GCa and PDAC models.

Indexed as

Biomarkers, TumorClaudinsPancreatic NeoplasmsRadiopharmaceuticalsStomach NeoplasmsAnimalsCell Line, TumorFemaleHumansMaleMiceMice, NudeMolecular ImagingRadioisotopesTissue DistributionZirconiumBiomarkers, TumorClaudinsCLDN18 protein, humanRadioisotopesRadiopharmaceuticalsZirconiumZirconium-89biomarkerclaudin 18.2gastric cancerpancreatic cancertheranostic

Identifiers

PMID41266253
PMCPMC12766881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.